1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Dr Hal Barron
| |||
b)
|
Position/status
|
Non-Executive Director
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GSK plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
| |||
b)
|
Nature of the transaction
|
Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
$34.4400
|
2,803.253
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume
Price
| |||||
e)
|
Date of the transaction
|
2023-11-16
| |||
f)
|
Place of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
James Ford
| |||
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GSK plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
| |||
b)
|
Nature of the transaction
|
Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
$34.4400
|
52.162
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume
Price
| |||||
e)
|
Date of the transaction
|
2023-11-16
| |||
f)
|
Place of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Dr Hal Barron
| |||
b)
|
Position/status
|
Non-Executive Director
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GSK plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
| |||
b)
|
Nature of the transaction
|
Acquisition of ADSs within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
$34.4400
|
71
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume
Price
| |||||
e)
|
Date of the transaction
|
2023-11-16
| |||
f)
|
Place of the transaction
|
New York Stock Exchange (XNYS)
|
GSK plc
| |
(Registrant)
| |
Date: November 21, 2023
| |
By:/s/ VICTORIA WHYTE
--------------------------
| |
Victoria Whyte
| |
Authorised Signatory for and on
| |
behalf of GSK plc
|
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
GSK plc published this content on 21 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 November 2023 16:11:13 UTC.